GFM
SRPT icon

GF Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

GF Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$39.8K Sell
2,217
-126
-5% -$2.38K ﹤0.01% 415
2026
Q1 		$51K Buy
2,343
+284
+14% +$5.5K ﹤0.01% 397
2025
Q4 		$44.3K Sell
2,059
-43
-2% -$906 ﹤0.01% 415
2025
Q3 		$40.5K Sell
2,102
-344
-14% -$6.13K ﹤0.01% 416
2025
Q2 		$41.8K Hold
2,446
– – ﹤0.01% 435
2025
Q1 		$156K Buy
2,446
+440
+22% +$46.3K ﹤0.01% 336
2024
Q4 		$244K Buy
+2,006
New +$246K 0.01% 272

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

GF Fund Management's SRPT Position: Q2 2026 in Review

GF Fund Management reduced its Sarepta Therapeutics (SRPT) stake by 5.4% in Q2 2026, selling an estimated $2.38K and leaving 2,217 shares worth $39.8K. The position accounts for ﹤0.01% of the portfolio, ranked #415.

GF Fund Management first reported a position in SRPT in Q4 2024 and has held it in 7 quarters since. The position peaked at $244K in Q4 2024. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • GF Fund Management held 2,217 shares of Sarepta Therapeutics worth $39.8K as of Q2 2026.
  • GF Fund Management sold 126 Sarepta Therapeutics shares in Q2 2026, an estimated $2.38K.
  • Sarepta Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #415 holding.
  • GF Fund Management first reported a position in Sarepta Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • GF Fund Management's Sarepta Therapeutics position peaked at $244K in Q4 2024.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.